Tag: Frankfurt:PF0

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsFrankfurt:PF0

GCL SI Showcases Scenario-Based PV Solutions at SNEC 2026, Driving Application-Specific Solar Deployment and Low-Carbon Development

GWM TANK 700 Hi4-T Wins 11 of 13 Stages at 2026 Taklimakan Rally

Leetx to Showcase Full-Stack Self-Developed Assembly Technology at Automotive Manufacturing 2026 in Bangkok

Tag: Frankfurt:PF0

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us